NASDAQ : RGC

Regencell Bioscience Holdings Limited — Company profile

Healthcare · Drug Manufacturers - Specialty & Generic · Hong Kong

Last price 6.71 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 3.33B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

Regencell Bioscience Holdings Limited focuses on the research, development, and commercialization of Traditional Chinese Medicine (TCM) in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, TCM brain theory, primarily for attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

Details

NameRegencell Bioscience Holdings Limited
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Employees10
Founded2014
Ipo Date2021-07-16
CeoYat-Gai Au
CountryHong Kong
ExchangeNASDAQ
Fiscal YearJuly - June
Reporting CurrencyUSD
Ipo Price9.50
IsinKYG7487R1002
CusipG7487R100
Cik1829667
Sic2833

Key executives

NameTitle
Yat-Gai AuFounder, Chairman and Chief Executive Officer
Michelle ChanFinancial Controller, Chief Financial Officer and Principal Financial Officer
Wai Hong ChungChief Operating Officer, Chief Strategy Officer and Director
Antonia AssangSenior Vice President of Project Management
Yat-Pui AuChief Business Officer

Contact

AddressChinachem Leighton Plaza, 9th Floor, Causeway Bay, Hong Kong
Phone852 2155 0823
Websitehttps://www.regencellbioscience.com